8-KFinancial EventsOther Events

ABBOTT LABORATORIES 8-K Report, Exit or Disposal Costs (Sep 21, 2010)

Filed September 21, 2010For Securities:ABT

Summary

Abbott Laboratories (ABT) has filed an 8-K report detailing a significant restructuring plan following its acquisition of Solvay's pharmaceuticals business. This plan aims to streamline operations, enhance efficiencies, and reduce costs across both former Solvay and existing Abbott commercial, R&D, and manufacturing functions. The company anticipates realizing the majority of savings by 2012. These restructuring efforts are expected to be largely consistent with the earnings-per-share accretion previously forecasted for the Solvay acquisition. Investors should note that Abbott expects to incur substantial pre-tax charges, estimated between $810 million and $970 million over the next two years, primarily related to employee costs, asset write-downs, and R&D program discontinuation. Additionally, one-time integration costs of approximately $310 million are expected for IT, support services, and operational alignment. Crucially, Abbott intends to classify these costs as "specified items," meaning they will not impact the company's ongoing earnings-per-share guidance for 2010.

Key Highlights

  • 1Abbott Laboratories announces a restructuring plan following the acquisition of Solvay's pharmaceuticals business to streamline operations and reduce costs.
  • 2The plan targets annual savings, with the majority expected by 2012, and is aligned with previously communicated EPS accretion forecasts for the Solvay acquisition.
  • 3Total pre-tax charges for the restructuring are estimated to be between $810 million and $970 million over the next two years.
  • 4These charges include significant employee-related costs (approx. $650 million), accelerated depreciation/asset write-downs (approx. $105 million), and other exit costs (up to $215 million).
  • 5Approximately $475 million to $640 million of these charges are expected in the second half of 2010, with about $430 million in Q3 2010.
  • 6One-time integration costs of approximately $135 million in H2 2010 and $175 million in 2011 are also anticipated for operational alignment.
  • 7Abbott will treat these restructuring and integration costs as "specified items," meaning they will not affect ongoing 2010 earnings-per-share guidance.

Frequently Asked Questions

The primary purpose of the restructuring plan is to streamline operations, improve efficiencies, and reduce costs across various functions (R&D, manufacturing, commercial, support) that were part of the recently acquired Solvay pharmaceuticals business, aligning them with Abbott's global pharmaceutical strategy.

The restructuring plan is expected to incur pre-tax charges of approximately $810 million to $970 million over the next two years. Additionally, one-time integration costs related to combining operations are estimated at $135 million in the second half of 2010 and $175 million in 2011, for a combined estimated total in the range of $1.12 billion to $1.28 billion.

No, Abbott expects to treat these costs as 'specified items.' As a result, they will not impact the company's ongoing earnings-per-share guidance for 2010.

A significant portion of the restructuring charges, approximately $475 million to $640 million, are forecast to occur in the second half of 2010, with roughly $430 million projected for the third quarter of 2010. Integration costs are spread across H2 2010 and 2011.